{"id":48024,"date":"2022-09-06T19:02:17","date_gmt":"2022-09-06T17:02:17","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/united-states-veterinary-oncology-market-trends-analysis-report-2022-a-171-16-million-market-by-2030-use-of-canines-as-a-model-for-clinical-trials-by-researchers-aiding-market-growth-researchand\/"},"modified":"2022-09-06T19:02:17","modified_gmt":"2022-09-06T17:02:17","slug":"united-states-veterinary-oncology-market-trends-analysis-report-2022-a-171-16-million-market-by-2030-use-of-canines-as-a-model-for-clinical-trials-by-researchers-aiding-market-growth-researchand","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/united-states-veterinary-oncology-market-trends-analysis-report-2022-a-171-16-million-market-by-2030-use-of-canines-as-a-model-for-clinical-trials-by-researchers-aiding-market-growth-researchand\/","title":{"rendered":"United States Veterinary Oncology Market Trends\/Analysis Report 2022: A $171.16 Million Market by 2030 – Use of Canines as a Model for Clinical Trials by Researchers Aiding Market Growth – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “U.S. Veterinary Oncology Market Size, Share & Trends Analysis Report by Therapy (Surgery, Radiology, Chemotherapy, Immunotherapy), by Animal Type (Canine, Feline), and Segment Forecasts, 2022-2030”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nThe U.S. veterinary oncology market size is expected to reach USD 171.16 million by 2030\n<\/p>\n

\nThe market is expected to expand at a CAGR of 8.7% from 2022 to 2030. The increasing prevalence of cancer in pets, willingness to spend on them by pet owners, and use of canines as a model for clinical trials by researchers are the key contributing factor toward the market growth.\n<\/p>\n

\nIn addition, a rise in the incidence of cancer in the feline population and rising pet ownership resulting in the increased focus on pet health is further expected to spur the growth. Moreover, companies are increasingly adopting strategies, such as M&As, research agreements, collaboration, partnerships, geographic expansion, and product development to enhance their market position.\n<\/p>\n

\nFor instance, in November 2020, Virbac publicized the approval of Stelfonta, a novel intratumoral injection treatment for canine mast cell tumors. In addition, Elanco purchased Aratana Therapeutics for its pet products pipeline. The company also had an agreement to create rabacfosadine (Tanovea), a drug from VetDC.\n<\/p>\n

\nIn addition, in July 2021, Elanco proclaimed that the FDA granted full approval of Tanovea for the lymphoma treatment in dogs. Hence, the market is expected to witness intense competition over the forecast period. The growing prevalence of cancer in companion animals is expected to propel the need for effective treatment options.\n<\/p>\n

\nIn canines, appendicular osteosarcoma is an extremely aggressive illness and curative-intent treatment comprises surgical resection of the tumor followed by chemotherapy to diminish the risk of tumor cells spreading to other areas, particularly the lungs. The golden retriever breed has been reported to have a high cancer prevalence compared to others.\n<\/p>\n

\nGolden Retriever is one of the favorite breeds in the U.S. and increasing concerns regarding the wellbeing of pets are contributing to the market growth. Clinical trials are a critical aspect of veterinary oncology. The accelerated number of clinical research involving surgical procedures in pets is further fueling the market growth.\n<\/p>\n

\nFor instance, in May 2019, Oregon State University conducted a research study stating that the risk of cancer recurrence reduced to 60% in dogs whose tumors were completely resected. With the growing number of pet parents in the U.S., animal health awareness is rising among people. In the U.S., various pet health awareness events are conducted to spread awareness, such as National Pet Week.\n<\/p>\n

\nThe FDA is alert that the COVID-19 pandemic may influence the ongoing studies being conducted to provision new animal drug development. Thereby, guidelines were issued in April 2020 to help diminish the potential impact of the pandemic on new animal drug development.\n<\/p>\n

\nU.S. Veterinary Oncology Market Report Highlights<\/strong>\n<\/p>\n